B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.